


# Product data sheet



MedKoo Cat#: 408146 Name: SRX3207 CAS#: 2254693-15-5 Chemical Formula: C <sub>29</sub> H <sub>29</sub> N <sub>7</sub> O <sub>3</sub> S Exact Mass: 555.2053 Molecular Weight: 555.66	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

## 1. Product description:

SRX3207 is a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression with IC<sub>50</sub> of 39.9 nM. SRX3207 demonstrates efficacy in multiple tumor models and represents a novel combinatorial approach to activate antitumor immunity. SRX3207 potently inhibited Syk and PI3K signaling and augmented the anti-tumor immune response in lung carcinoma tumor model with no toxicity.

## 2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

## 3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	5	9

## 4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.10 mL	10.51 mL	21.03 mL
5 mM	0.42 mL	2.10 mL	4.21 mL
10 mM	0.21 mL	1.05 mL	2.10 mL
50 mM	0.04 mL	0.21 mL	0.42 mL

## 5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

## 6. Recommended literature which reported protocols for in vitro and in vivo study

### In vitro study

- Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. *Mol Cancer Ther.* 2020 Mar;19(3):755-764. doi: 10.1158/1535-7163.MCT-19-0947. Epub 2020 Jan 23. PMID: 31974273; PMCID: PMC7450492.

### In vivo study

To be determined

## 7. Bioactivity

### Biological target:

SRX3207 is a Syk/PI3K inhibitor, with IC<sub>50</sub> values of 10.7 nM and 861 nM for Syk and PI3K $\alpha$ , respectively.

### In vitro activity

This study developed in silico the dual Syk/PI3K inhibitor, SRX3207, for the combinatorial inhibition of Syk and PI3K in one small molecule.

# Product data sheet



Reference: Mol Cancer Ther. 2020 Mar;19(3):755-764. <https://pubmed.ncbi.nlm.nih.gov/31974273/>

In vivo activity

---

To be determined

*Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.*